• Publications
  • Influence
Bone quality--the material and structural basis of bone strength and fragility.
This review discusses advances in knowledge regarding the composition and structure of bone, the modeling and remodeling of bone, the formation of bone during growth and its reconstruction in adults,
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial
It is indicated that raloxifene treatment over 3 years not only preserves bone mass but also lowers the risk of new vertebral fractures in postmenopausal women with osteoporosis, regardless of whether they have had fractures before starting treatment.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures and was associated with a significant improvement in bone mineral density and bone metabolism markers.
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.
HR-pQCT appears promising to assess bone density and microarchitecture at peripheral sites in terms of reproducibility and ability to detect age- and disease-related changes.
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
SummaryGuidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis.IntroductionThe International Osteoporosis
Body mass index as a predictor of fracture risk: A meta-analysis
It is concluded that low BMI confers a risk of substantial importance for all fractures that is largely independent of age and sex, but dependent on BMD.
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate in osteoporotic women with prevalent vertebral fracture.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation
In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture and was associated with a lower incidence of breast cancer.
Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women
The effects of supplementation with vitamin D3 (cholecalciferol) and calcium on the frequency of hip fractures and other nonvertebral fractures, identified radiologically, in 3270 healthy ambulatory women are studied.